How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
Pancreatic Cancer News
PANCREATIC CANCER ADVISOR
Pancreatic Cancer News
Durvalumab-Tremelimumab Plus Chemotherapy Failed to Improve Survival in Pancreatic Cancer Subtype
Durvalumab plus tremelimumab added to chemotherapy did not improve survival or response in metastatic pancreatic cancer, according to results of a phase 2 trial.
Potential Markers for High Risk of Pancreatic Cancer Identified
Using cohorts from 2 large observational studies, researchers investigated whether duration of diabetes and extent of weight loss may be a marker of risk for pancreatic cancer.
How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Zenocutuzumab Gets Orphan Drug Designation for Pancreatic Cancer
Zenocutuzumab is a first-in-class bispecific antibody that binds to HER2 and HER3 receptors, thereby blocking the interaction of HER3 with its ligand neuregulin 1 (NRG1) or NRG1-fusion proteins.
Why Cancer Centers May Need to Rethink the Hard Sell to Patients
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
NALIRIFOX Shows Promising Anticancer Activity in Metastatic Pancreatic Ductal Adenocarcinoma
The NALIRIFOX chemotherapy regimen includes liposomal irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin.
Has the Time for At-Home Cancer Care Finally Come?
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Neoadjuvant Treatment of Borderline-Resectable Pancreatic Cancer Led to Improved Overall Survival
Neoadjuvant treatment with GEMCAP, FOLFIRINOX, or capecitabine plus radiotherapy prolonged OS compared with immediate surgery in patients with pancreatic cancer.
New-Onset Type 2 Diabetes as a Potential Biomarker in Pancreatic Cancer
The study results suggest that patients with weight loss after age 50 years in the context of new-onset type 2 diabetes may be good candidates for pancreatic cancer screening.
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Clinical, Genetic, Biomarker Model IDs Risk for Pancreatic Cancer
Area under the ROC curve estimated by cross-validation was 0.62 for multifactor model.
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
Federal Ruling Puts Pressure on Clinical Trial Sponsors to Post Data
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
Treatment Options for Pancreatic Neuroendocrine Tumors
In the management of PNETs it is important to differentiate between functional and nonfunctional PNETs in order to determine the course of treatment.
First Human Clinical Trial in US to Test the Use of CRISPR-Modified T Cells in Cancer Answers Vital Questions
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Improving Cancer Pain Management Amid the Opioid Crisis
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
A New Trend in Drug Development: Leveraging Data from Expanded Access
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
Evidence Suggests B Cells Play a Role in Immunotherapy Response
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Pancreatic Cancer
